Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Early and accurate diagnosis is a priority in improving treatment response and in slowing down neurodegeneration and disease progression, regardless of outstanding advancements in therapeutics. Recent ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...

Biomarker development is hardly coextensive with drug development, but in every developmental stage—from exploratory research to clinical trial to therapeutic application—there is significant overlap.

For much of the past century, Alzheimer's disease has been one of medicine's most daunting frontiers—biologically complex, ...

As molecular biomarkers go, proteins are possibly the most universally affected by disease state. Protein signatures encompass not only total levels of expression, but predominance of different ...

Precision medicine has revolutionized the landscape of neurological care, shifting from “one-size-fits-all” approaches to ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...